Drug intelligence / Profile preview

SOL-001

Development stage: Preclinical
Lead developer: Soley Therapeutics

Overview

SOL-001 is a biological product under development by Soley Therapeutics. It acts as a cell cycle inhibitor and is being investigated primarily for oncology and related indications. The drug's mechanism of action involves inhibition of the cell cycle, which can prevent the proliferation of cancer cells. Its primary therapeutic areas include neoplasms (cancers), respiratory diseases, and skin and musculoskeletal diseases. As of May 2025, its highest global R&D status is preclinical, with active indications including bladder cancer, melanoma, and non-small cell lung cancer[1].

Beyond the preview

Go deeper on SOL-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOL-001.

Explore the full profile